Eckert & Ziegler's GalliaPharm(R) to Be Distributed by Jubilant Radiopharma(TM) in Canada

Berlin, Germany & Montreal, Quebec--(Newsfile Corp. - August 31, 2020) - Eckert & Ziegler Radiopharma GmbH and Jubilant Radiopharma, a wholly-owned unit of Jubilant Pharma Limited, signed an agreement for the exclusive distribution of Eckert & Ziegler's proprietary generator "GalliaPharm®" in Canada by Jubilant Radiopharma to meet the growing demand of this unique product.

Figure 1

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6522/62875_a0bc9fe4f6edfbdb077fad3a1f54.jpg

GalliaPharm^® has recently been approved by Health Canada for in-vitro radiolabeling of carrier molecules for diagnostic procedures using positron emission tomography (PET). This major advance for specialists in nuclear medicine and functional molecular medical imaging will allow for the labelling of molecular vectors used in the diagnosis of neuroendocrine cancers, which are particularly difficult to detect early. It is also used for the clinical development of other molecular vectors such as in the diagnosis of prostate cancer (recurrent forms), the most common cancer in men.

GalliaPharm^® is a closed system consisting of pharmacopoeia grade borosilicate glass column containing a titanium dioxide bed on which ⁶⁸Ge is adsorbed. ⁶⁸Ga is continuously produced by decay of its radioactive parent ⁶⁸Ge and is eluted with sterile ultrapure 0,1 mol/l hydrochloric acid. GalliaPharm^® is available with the following activities: 740 MBq, 1110 MBq, 1480 MBq and 1850 MBq (20 mCi, 30 mCi, 40 mCi, 50 mCi). It is registered as a medicinal product in 17 European countries. Eckert & Ziegler Radiopharma GmbH is also a holder of a Type II Drug Master File (#28741) in the USA.

Dr. Harald Hasselmann, member of the executive board and responsible for the business segment Medical stated, "We are pleased to have received the Notice of Compliance from Health Canada for GalliaPharm^®. Canada is an important market and with the approval, we are able to answer the growing demand for ⁶⁸Ga-based diagnostics. We are very happy that, with Jubilant Radiopharma, we have found a local partner who provides both, highest expertise in radiopharmaceuticals and a strong network of specialists to satisfy our customers."

Sergio Calvo, President of Jubilant Radiopharma's Radiopharmaceuticals Division, stated, "Eckert & Ziegler's GalliaPharm^® is an excellent addition to our PET portfolio, which includes RUBY-FILL^® for advanced myocardial perfusion imaging. GalliaPharm^® will provide expanded access of PET in Canada and will enhance the way patients with known neuroendocrine cancers are both diagnosed and managed."

"This agreement is another landmark event for Jubilant Radiopharma, supporting its ongoing commitment to the global expansion and utility of nuclear medicine and PET imaging. Our goal is to grow SPECT and PET imaging globally by providing products that enable physicians to deliver high quality diagnostic studies as part of our mission of Improving Lives through Nuclear Medicine," stated Pramod Yadav, CEO Jubilant Pharma Limited.

About Eckert & Ziegler Radiopharma GmbH

Eckert & Ziegler Radiopharma GmbH is a wholly-owned subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG and part of Eckert & Ziegler's Medical business segment. The company is specialized in the field of nuclear medicine and molecular imaging, providing radiopharmaceuticals and radiochemicals for diagnosis, treatment and research purposes. With the GalliaPharm® Ge-68/Ga-68 generator and Yttriga, sterile Yttrium-90 chloride solution, Radiopharma GmbH provides two core pharmaceutical products for diagnosis and therapy.

About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non Sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radiopharmacies in the US. The Company has a team of around 5,200 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

About Jubilant Radiopharma

Jubilant Radiopharma, Radiopharmaceutical Division of Jubilant Pharma Ltd., is an industry-leading radiopharmaceutical business focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of "Improving Lives Through Nuclear Medicine" on a global scale. The company is the market leader in North America for I-131 products (diagnosis and treatment of thyroid disorder and cancer), MAA (lung perfusion imaging), DTPA (renal, Brain imaging) and MDP (bone imaging), and also markets other products such as Sestamibi (myocardial perfusion imaging), Gluceptate (brain and renal imaging), and Rubidium-82 Generator (PET Cardiology).

For further information

Contact Eckert & Ziegler

Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Straße 10
13125 Berlin
Germany
Phone: +49 30 941084 0
Fax: +49 30 941084 470
Email: info.radiopharma@ezag.de

Contact Jubilant Radiopharma

Jubilant Radiopharma^TM
Robert Sgroi, Director of Marketing
E-mail: robert.sgroi@jubl.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62875